Cassava Sciences has settled SEC charges related to misleading statements about its Alzheimer’s drug, simufilam. The company paid $40 million and is now focusing on the drug’s development. HC Wainwright upgraded Cassava’s stock to ‘Buy’ due to positive expectations for the upcoming clinical trial results.